Curanex Pharmaceuticals Inc. (NASDAQ: CURX) regained compliance with Nasdaq’s minimum-bid-price requirement after its common stock maintained a closing bid of at least $1.00 per share. Nasdaq Staff determined that the listing issue was resolved, and the matter is now closed.
Dare Bioscience, Inc. (NASDAQ: DARE) registered the potential resale by selling stockholders of up to 8,934,345 common shares. The shares are issuable when holders exercise common warrants and placement agent warrants. Cash exercises could provide Dare Bioscience with up to approximately $12.4 million, while …
Definium Therapeutics, Inc. (NASDAQ: DFTX) awarded Chief Executive Officer Robert Barrow 40,000 shares at $0 on Sept. 2. His reported ownership stood at 1,513,663 shares after the award, before a separate transaction the next day.
Director Chell Jeffrey W. was awarded 61,600 Actinium Pharmaceuticals, Inc. (AMEX: ATNM) shares at $0 per share.
Alector, Inc. (NASDAQ: ALEC) saw Principal Accounting Officer Wong-Sarad Grace sell 9,446 shares across three transactions. The sales were conducted under transaction code S.
Alector, Inc. (NASDAQ: ALEC) CFO and Chief Business Officer Berkley Neil Lindsay sold 29,251 shares at $2.66 per share on 3 September 2026. The transaction left Lindsay with ownership of 350,649 Alector shares.
AN2 Therapeutics, Inc. (NASDAQ: ANTX) recorded a 272-share sale by Sarah Joanne Williams at $5.53 per share. The filing identifies Williams as the company’s principal accounting officer.
Ardent Health, Inc. (NYSE: ARDT) now presents 2025 Adjusted EBITDA at $447.3 million, down from $545.0 million, after removing $97.7 million tied to two non-GAAP adjustments. The removed adjustments related to a change in the collectability estimate forAccounts Receivableand a New Mexico professionalLiabilityaccrual. The …
SEACOR Marine Holdings Inc. (NYSE: SMHI) saw Everett Andrew H II sell 4,116 shares at $10 per share. Andrew is the company’s senior vice president, general counsel and secretary.
Actinium Pharmaceuticals, Inc. (AMEX: ATNM) awarded Steinhart Richard I 62,800 shares at $0 per share on September 2, 2026. The filing also reports an award of 94,200 derivative securities to Steinhart Richard I on the same date.